Literature DB >> 6608859

Non-ionic water soluble contrast medium 3-deoxy-3-iodo-D-glucose (DIG) for use in the CSF space. An experimental study with mongrel and beagle dogs.

S Suzuki, K Ebina, T Sekiya, T Iwabuchi.   

Abstract

A non-ionic water soluble contrast medium, 3-Deoxy-3-Iodo-D-Glucose (DIG), was experimentally evaluated for use in the cerebrospinal fluid (CSF) space, and compared with other contrast media. Two ml (180 mgI/ml) of DIG were injected either intraventricularly or intracisternally in 15 adult mongrel dogs (average weight: 6.4 kg), and X-ray photographic, CSF, EEG, and histological studies were then performed. Additional tests were made on four beagle dogs (average weight: 9.8 kg), focussing particularly on changes in cell count and protein in the CSF following alternate intracisternal injections of 2 ml (170 mgI/ml) of DIG and metrizamide (Amipaque), and on epileptogenicity following intracisternal injection of 3 ml (300 mgI/ml) of DIG. That DIG provides adequate definition was demonstrated both by the ventriculograms and cisternograms, and by comparison with metrizamide. Neither epileptic discharges in the EEG nor epileptic symptoms were seen in any of the dogs used in the studies. In the CSF drawn 24 hours after the injection, protein tended to increase moderately with DIG, but pleocytosis was mild with both media. Histological studies of the central nervous system structures around the cisterna magna revealed no definite abnormal findings. Neither fibrosis nor arachnoid adhesions were seen in scanning electron microscopic observations of the basal subarachnoid spaces.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608859     DOI: 10.1007/bf01406654

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  12 in total

1.  Ventriculography with non-ionic water-soluble contrast medium, Amipaque (metrizamide). Comparative experimental and clinical studies.

Authors:  S Suzuki; K Ito; T Iwabuchi
Journal:  J Neurosurg       Date:  1977-07       Impact factor: 5.115

2.  Lumbar myelography with meglumine iocarmate and metrizamide.

Authors:  T Hindmarsh
Journal:  Acta Radiol Diagn (Stockh)       Date:  1975-05

3.  Spinal seizures after metrizamide myelography in a patient with a spinal block.

Authors:  M R Paling; E A Quindlen; G Di Chiro
Journal:  AJR Am J Roentgenol       Date:  1980-11       Impact factor: 3.959

4.  Confusion, myoclonus and speech arrest: epileptic manifestations after metrizamide myelography.

Authors:  U Bergvall; T Brismar; U Lying-Tunell; E Valdimarsson
Journal:  Acta Neurol Scand       Date:  1981-05       Impact factor: 3.209

5.  Asterixis of myoclonus after metrizamide myelography.

Authors:  M Gimenez; F Martinez; M Feijoo
Journal:  Arch Neurol       Date:  1981-07

6.  Metrizamide encephalopathy.

Authors:  F M Vincent; J E Zimmerman
Journal:  Ann Neurol       Date:  1980-05       Impact factor: 10.422

7.  Ventriculography with methylglucamine iocarmate (Dimer-X). Experimental and clinical study.

Authors:  S Suzuki; S Kawaguchi; R Mita; T Iwabuchi
Journal:  Acta Neurochir (Wien)       Date:  1976       Impact factor: 2.216

8.  Metrizamide-phenothiazine interaction. Report of a case with seizures following myelography.

Authors:  T Hindmarsh; A Grepe; L Widén
Journal:  Acta Radiol Diagn (Stockh)       Date:  1975-03

9.  Complex partial status epilepticus following myelography with metrizamide.

Authors:  D Russell; I M Anke; R Nyberg-Hansen; O Slettnes; O Sortland; T Veger
Journal:  Ann Neurol       Date:  1980-09       Impact factor: 10.422

10.  Asterixis and encephalopathy following metrizamide myelography: investigations into possible mechanisms and review of the literature.

Authors:  J M Bertoni; R J Schwartzman; G Van Horn; J Partin
Journal:  Ann Neurol       Date:  1981-04       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.